Login to Your Account

Celgene Hat Trick: Pomalyst Joins Multiple Myeloma Arsenal

By Marie Powers
Staff Writer

Friday, February 8, 2013

In October 2012, the FDA cancelled the Oncologic Drugs Advisory Committee meeting scheduled for Nov. 8, which was to include a review of the new drug application for pomalidomide, Celgene Corp.'s immunomodulatory drug (IMiD) candidate in multiple myeloma (MM).

Notification came in the aftermath of Hurricane Sandy, which played havoc not only with lives and property up and down the East Coast, but also with business and government schedules, including adcom meetings.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription